EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET FORECAST 2019-2028

  • You are here:
  • Home
  • Reports
  • EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET FORECAST 2019-2028

EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET FORECAST 2019-2028

The Europe molecular point of care diagnostics market is predicted to project growth at a CAGR of 15.21% during the forecast period, 2019-2028. The factors favoring the growth of the market are the significant efforts put forth by major countries of the region to enhance the adoption of precision medicine solutions, and the growing demands for targeted therapeutics. The latter factor has resulted in the launch of research and development programs by pharmaceutical manufacturers, research organizations, and biotechnology companies.

EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET FORECAST 2019-2028

Europe Molecular Point of Care Diagnostics Market by Technology (Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification Technology, Other) by Product (Assays, Instruments, Software)  by Application (Infectious Disease, Oncology, Prenatal, Others) by End-user (Hospitals, Clinics, Diagnostics Centres, Others) and by Geography.

Request free sample

The Europe molecular point of care diagnostics market is predicted to project growth at a CAGR of 15.21% during the forecast period, 2019-2028. The factors favoring the growth of the market are the significant efforts put forth by major countries of the region to enhance the adoption of precision medicine solutions, and the growing demands for targeted therapeutics. The latter factor has resulted in the launch of research and development programs by pharmaceutical manufacturers, research organizations, and biotechnology companies.
Europe Molecular Point of Care Diagnostics Market

To know more about this report, request a free sample copy

The countries evaluated for market analysis in the Europe molecular point of care diagnostics market are Germany, Poland, Belgium, Italy, Russia, France, the United Kingdom, and the rest of Europe. In the UK, the technological integration in the molecular point of care diagnostics evaluation process, in terms of appraisal for associated targeted drug, avoids delay in the decision-making process. In accordance with the government initiatives, the Medicines & Healthcare products Regulatory Agency (MHRA) has implemented an evaluation program, with regard to the molecular diagnostics point of care tests, when various tests for the same biomarker are available. The availability of temporary funding and reimbursement for disruptive technologies is estimated to positively impact the growth of the market. In France, the availability of broad reimbursement coverage makes it more viable to greater market penetration rates of molecular diagnostics in comparison to other European countries. The active involvement of private and public companies are further strengthening the rate of adoption of molecular diagnostics point of care. In Poland, the increasing demand for long-term care services, due to the growing aging population, rising incidence of chronic diseases, and the rising number of one-person households, are influencing the growth of the market.

Hoffmann-La Roche Ltd is a science and technology innovator that manufactures, markets, and designs pharmaceuticals and diagnostics across the world. The company supplies PCR-based instruments and kits majorly for infectious diseases. The product portfolio of the company includes, Cobas Liat PCR System, cobas EGFR Mutation Test v2, cobas Influenza A/B Assay, cobas Strep A Assay, etc.

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

  1. RESEARCH SCOPE & METHODOLOGY
    • STUDY OBJECTIVES
    • SCOPE OF STUDY
    • METHODOLOGY
    • ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    • MARKET SIZE & ESTIMATES
    • MARKET OVERVIEW
  3. MARKET DYNAMICS
    • MARKET DEFINITION
    •    KEY DRIVERS
      • DEMAND FROM GOVERNMENTS FOR DIAGNOSING COVID-19 POSITIVE PATIENTS
      • RISE IN DEMAND FOR NON-INVASIVE DIAGNOSIS
      • GROWTH IN THE NUMBER OF DISEASES
      • FUNDING FOR RESEARCH AND DEVELOPMENT
      • TECHNOLOGICAL ADVANCEMENTS IN THE MARKET
    •    KEY RESTRAINTS
      • HIGH CAPITAL REQUIREMENT
      • LACK OF HIGH COMPLEXITY TESTING CENTERS
  1. KEY ANALYTICS
    • KEY INVESTMENT INSIGHTS
    •    PORTER’S FIVE FORCE ANALYSIS
      • BUYER POWER
      • SUPPLIER POWER
      • SUBSTITUTION
      • NEW ENTRANTS
      • INDUSTRY RIVALRY
    • OPPORTUNITY MATRIX
    • VENDOR LANDSCAPE
    • REGULATORY FRAMEWORK
  2. MARKET BY TECHNOLOGY
    •    POLYMERASE CHAIN REACTION
      • REAL TIME PCR
      • DIGITAL PCR
    • ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
    • OTHER
  3. MARKET BY PRODUCT
    • ASSAYS
    • INSTRUMENTS
    • SOFTWARE
  4. MARKET BY APPLICATION
    •    INFECTIOUS DISEASE
      • RESPIRATORY
      • HOSPITAL ACQUIRED INFECTIONS
      • SEXUALLY TRANSMITTED INFECTIONS
      • GASTRO INTESTINAL INFECTIONS
    • ONCOLOGY
    • PRENATAL
    • OTHERS
  5. MARKET BY END-USER
    • HOSPITALS
    • CLINICS
    • DIAGNOSTICS CENTRES
    • OTHERS
  6. GEOGRAPHICAL ANALYSIS
    •    EUROPE
      • UNITED KINGDOM
      • GERMANY
      • FRANCE
      • ITALY
      • RUSSIA
      • BELGIUM
      • POLAND
      • REST OF EUROPE
  1. COMPANY PROFILES
    • ABBOTT LABORATORIES
    • ABACUS DIAGNOSTICA
    • BIOMÉRIEUX SA
    • BIOCARTIS NV
    • DANAHER CORPORATION
    • DIASORIN SPA
    • BIO-RAD
    • F HOFFMANN-LA ROCHE AG
    • LUMINEX CORPORATION
    • HOLOGIC INC
    • MESA BIOTECH
    • SPARTAN BIOSCIENCES INC
    • QUANTUMDX GROUP LTD
    • QUIDEL CORPORATION
    • QIAGEN NV

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – MOLECULAR POINT OF CARE DIAGNOSTICS

TABLE 2: EMERGENCY USE AUTHORISATION FOR DIAGNOSTICS BY FDA

TABLE 3: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 4: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 5: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PCR TECHNOLOGY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 6: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PCR TECHNOLOGY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 7: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 8: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 9: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 10: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 11: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 12: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 13: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 14: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 15: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 16: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

LIST OF FIGURES

FIGURE 1: KEY INVESTMENT INSIGHTS

FIGURE 2: PORTER’S FIVE FORCE ANALYSIS

FIGURE 3: VALUE PROPOSITION – LABORATORY, IMMUNOASSAY, AND MOLECULAR POC DIAGNOSTIC

FIGURE 4: OPPORTUNITY MATRIX

FIGURE 5: VENDOR LANDSCAPE

FIGURE 6: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2018

FIGURE 7: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2019-2028 (IN $ MILLION)

FIGURE 8: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY PCR TECHNOLOGY, IN 2018

FIGURE 9: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY REAL TIME PCR, 2019-2028 (IN $ MILLION)

FIGURE 10: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY DIGITAL PCR, 2019-2028 (IN $ MILLION)

FIGURE 11: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, 2019-2028 (IN $ MILLION)

FIGURE 12: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHER, 2019-2028 (IN $ MILLION)

FIGURE 13: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2018

FIGURE 14: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ASSAYS, 2019-2028 (IN $ MILLION)

FIGURE 15: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INSTRUMENTS, 2019-2028 (IN $ MILLION)

FIGURE 16: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY SOFTWARE, 2019-2028 (IN $ MILLION)

FIGURE 17: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2018

FIGURE 18: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, 2019-2028 (IN $ MILLION)

FIGURE 19: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY INFECTIOUS DISEASE, IN 2018

FIGURE 20: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY RESPIRATORY, 2019-2028 (IN $ MILLION)

FIGURE 21: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY HOSPITAL ACQUIRED INFECTIONS, 2019-2028 (IN $ MILLION)

FIGURE 22: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY SEXUALLY TRANSMITTED INFECTIONS, 2019-2028 (IN $ MILLION)

FIGURE 23: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY GASTRO INTESTINAL INFECTIONS, 2019-2028 (IN $ MILLION)

FIGURE 24: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ONCOLOGY, 2019-2028 (IN $ MILLION)

FIGURE 25: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRENATAL, 2019-2028 (IN $ MILLION)

FIGURE 26: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)

FIGURE 27: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY END-USER, IN 2018

FIGURE 28: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY HOSPITALS, 2019-2028 (IN $ MILLION)

FIGURE 29: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY CLINICS, 2019-2028 (IN $ MILLION)

FIGURE 30: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY DIAGNOSTIC CENTRES, 2019-2028 (IN $ MILLION)

FIGURE 31: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)

FIGURE 32: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2019 & 2028  (IN %)

FIGURE 33: UNITED KINGDOM MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 34: GERMANY MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 35: FRANCE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 36: ITALY MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 37: RUSSIA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 38: BELGIUM MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 39: POLAND MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 40: REST OF EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

  1. GEOGRAPHICAL ANALYSIS
    •    EUROPE
      • UNITED KINGDOM
      • GERMANY
      • FRANCE
      • ITALY
      • RUSSIA
      • BELGIUM
      • POLAND
      • REST OF EUROPE
  1. MARKET BY TECHNOLOGY
    •    POLYMERASE CHAIN REACTION
      • REAL TIME PCR
      • DIGITAL PCR
    • ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
    • OTHER
  2. MARKET BY PRODUCT
    • ASSAYS
    • INSTRUMENTS
    • SOFTWARE
  3. MARKET BY APPLICATION
    •    INFECTIOUS DISEASE
      • RESPIRATORY
      • HOSPITAL ACQUIRED INFECTIONS
      • SEXUALLY TRANSMITTED INFECTIONS
      • GASTRO INTESTINAL INFECTIONS
    • ONCOLOGY
    • PRENATAL
    • OTHERS
  4. MARKET BY END-USER
    • HOSPITALS
    • CLINICS
    • DIAGNOSTICS CENTRES
    • OTHERS

To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now